SP100
Basic information
Region (hg38): 2:230415942-230545606
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SP100 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 53 | 10 | 63 | |||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 54 | 10 | 1 |
Variants in SP100
This is a list of pathogenic ClinVar variants found in the SP100 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-230416310-G-T | not specified | Uncertain significance (Sep 16, 2021) | ||
2-230442991-C-A | not specified | Uncertain significance (Dec 20, 2023) | ||
2-230443038-A-C | not specified | Uncertain significance (Sep 26, 2022) | ||
2-230444191-C-G | not specified | Uncertain significance (Mar 12, 2024) | ||
2-230444289-G-A | not specified | Uncertain significance (Dec 09, 2023) | ||
2-230444331-A-G | not specified | Likely benign (Dec 07, 2021) | ||
2-230446855-A-G | not specified | Likely benign (Dec 09, 2023) | ||
2-230446857-G-C | not specified | Uncertain significance (Aug 20, 2024) | ||
2-230446869-G-A | not specified | Uncertain significance (Mar 27, 2023) | ||
2-230449091-C-T | not specified | Uncertain significance (Feb 06, 2023) | ||
2-230449096-G-A | not specified | Uncertain significance (Sep 03, 2024) | ||
2-230449109-G-A | not specified | Likely benign (May 18, 2022) | ||
2-230449564-C-A | not specified | Uncertain significance (Dec 19, 2022) | ||
2-230449570-C-T | not specified | Uncertain significance (Jun 24, 2022) | ||
2-230449572-C-T | not specified | Uncertain significance (Aug 12, 2024) | ||
2-230450179-C-G | not specified | Uncertain significance (Aug 08, 2022) | ||
2-230461316-G-A | Likely benign (Jan 05, 2018) | |||
2-230461336-G-A | not specified | Uncertain significance (Dec 09, 2023) | ||
2-230461342-C-A | not specified | Uncertain significance (May 06, 2024) | ||
2-230461378-G-C | not specified | Uncertain significance (Feb 28, 2024) | ||
2-230461379-C-A | not specified | Uncertain significance (Apr 04, 2023) | ||
2-230461408-A-G | not specified | Uncertain significance (Aug 20, 2024) | ||
2-230462459-G-A | not specified | Likely benign (Nov 28, 2023) | ||
2-230462469-C-T | Benign (Jul 29, 2018) | |||
2-230464096-A-G | not specified | Uncertain significance (Aug 04, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SP100 | protein_coding | protein_coding | ENST00000340126 | 29 | 128149 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.76e-12 | 1.00 | 125193 | 2 | 551 | 125746 | 0.00220 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.597 | 426 | 462 | 0.922 | 0.0000231 | 5911 |
Missense in Polyphen | 56 | 54.733 | 1.0231 | 587 | ||
Synonymous | 1.42 | 141 | 164 | 0.859 | 0.00000892 | 1501 |
Loss of Function | 3.55 | 29 | 58.3 | 0.498 | 0.00000299 | 707 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00341 | 0.00341 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000113 | 0.000109 |
Finnish | 0.00213 | 0.00208 |
European (Non-Finnish) | 0.00365 | 0.00363 |
Middle Eastern | 0.000113 | 0.000109 |
South Asian | 0.0000694 | 0.0000653 |
Other | 0.00245 | 0.00245 |
dbNSFP
Source:
- Function
- FUNCTION: Together with PML, this tumor suppressor is a major constituent of the PML bodies, a subnuclear organelle involved in a large number of physiological processes including cell growth, differentiation and apoptosis. Functions as a transcriptional coactivator of ETS1 and ETS2 according to PubMed:11909962. Under certain conditions, it may also act as a corepressor of ETS1 preventing its binding to DNA according to PubMed:15247905. Through the regulation of ETS1 it may play a role in angiogenesis, controlling endothelial cell motility and invasion. Through interaction with the MRN complex it may be involved in the regulation of telomeres lengthening. May also regulate TP53- mediated transcription and through CASP8AP2, regulate FAS-mediated apoptosis. Also plays a role in infection by viruses, including human cytomegalovirus and Epstein-Barr virus, through mechanisms that may involve chromatin and/or transcriptional regulation. {ECO:0000269|PubMed:11909962, ECO:0000269|PubMed:14647468, ECO:0000269|PubMed:15247905, ECO:0000269|PubMed:15592518, ECO:0000269|PubMed:15767676, ECO:0000269|PubMed:16177824, ECO:0000269|PubMed:17245429, ECO:0000269|PubMed:21274506, ECO:0000269|PubMed:21880768}.;
- Pathway
- Viral carcinogenesis - Homo sapiens (human);Herpes simplex infection - Homo sapiens (human);Cytokine Signaling in Immune system;SUMOylation of DNA damage response and repair proteins;Post-translational protein modification;SUMO E3 ligases SUMOylate target proteins;Metabolism of proteins;Immune System;SUMOylation;regulation of transcriptional activity by pml;Interferon gamma signaling;Interferon Signaling
(Consensus)
Intolerance Scores
- loftool
- 0.494
- rvis_EVS
- 0.23
- rvis_percentile_EVS
- 68.57
Haploinsufficiency Scores
- pHI
- 0.763
- hipred
- Y
- hipred_score
- 0.622
- ghis
- 0.532
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.978
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sp100
- Phenotype
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;telomere maintenance;DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator;negative regulation of endothelial cell migration;viral process;response to type I interferon;response to interferon-gamma;negative regulation of DNA binding;negative regulation of DNA-binding transcription factor activity;maintenance of protein location;regulation of angiogenesis;positive regulation of transcription, DNA-templated;negative regulation of protein export from nucleus;negative regulation of cellular component movement;interferon-gamma-mediated signaling pathway;type I interferon signaling pathway;regulation of extrinsic apoptotic signaling pathway via death domain receptors;regulation of Fas signaling pathway
- Cellular component
- nuclear chromosome, telomeric region;nucleus;nucleoplasm;cytoplasm;nuclear body;PML body;Mre11 complex
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA binding;protein binding;kinase binding;protein domain specific binding;protein dimerization activity;chromo shadow domain binding